ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC
A phase 3 trial of Dacomitinib and Gefitinib in Non-small-cell lung cancer, run by Pfizer, completed.
Overview
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC is a phase 3 interventional study registered as NCT01774721 by Pfizer, with 452 participants recorded, started 2013-05-09 and reaching its primary completion in 2016-07-29. Interventions recorded: Dacomitinib (PF-00299804), Gefitinib. Conditions recorded: Non-small Cell Lung Cancer With EGFR-Activating Mutations.
Linked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
Shares Dacomitinib, Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TrialEGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
Shares Dacomitinib, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TreatmentPF-07248144
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TreatmentPF-08046054
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Shares Gefitinib and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.